Modifications in tissue kallikrein activity with indomethacin and prednisolone treatment in arthritic rats

Inflammopharmacology

Volumn 18, Issue 3, 2010, Pages 113-117

  Sharma, J N ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Adjuvant arthritis; Indomethacin; Inflammation; Prednisolone; Rats; Tissue kallikrein

Indexed keywords

INDOMETACIN; KALLIKREIN; PREDNISOLONE;

ADJUVANT ARTHRITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME MODIFICATION; FOREFOOT; JOINT SWELLING; KNEE ARTHRITIS; MALE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; SYNOVIAL BURSA; TISSUE LEVEL; TREATMENT DURATION;

EID: 77955658186     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-010-0034-8     Document Type: Article

References (20)

1. Al-Haboubi HA, Bennett D, Sharma JN et al (1986) A synovial amidase acting on tissue kallikrein-selective substrate in clinical and experimental arthritis. Adv Exp Med Biol B 198:404-411
2. Amundsen E, Putter J, Friberger P et al (1979) Method for determination of glandular kallikrein by means of chromogenic tripeptide substrate. Adv Exp Med Biol A 120:83-95
3. Edery H, Lewis GP (1963) Kinin-forming activity and histamine in lymph after tissue injury. J Physiol 169:568-573
4. Farmer SG, Burch RM, meeker SA et al (1989) Evidence for a pulmonary B3 bradykinin receptor. Mol Pharmacol 36:1-8
5. Newbould BB (1963) Chemotherapy of arthritis induced in rats by injection of Mycobacterial adjuvant. Br J Pharmacol 21:127-136
6. Regoli D, Barabe J (1980) Pharmacology of bradykinin and related kinins. Pharmacol Rev 32:1-46
7. Sharma JN (1991) The role of kinin system in joint inflammatory disease. Eur J Rheumatol Inflamm 11:30-37
8. Sharma JN (1993) Therapeutic prospects of bradykinin receptor antagonists. Gen Pharmacol 24:267-274
9. Sharma JN (2005) The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection. Inflammopharmacology 12:591-596
10. Sharma JN, Buchanan WW (1994) Pathogenic responses of bradykinin system in chronic inflammatory rheumatoid disease. Exp Toxicol Pathol 46:421-433
11. Sharma JN, Sharma JN (1977) Comparison of anti-inflammatory activity of Commiphora mukul (an indigenous drug) with those of phenylbutazone and ibuprofen in experimental arthritis induced by Mycobacterial adjuvant. Arzneim-Forsh 27:1455-1457
12. Sharma JN, Wirth KJ (1996) Inhibition of rats adjuvant arthritis by a bradykinin antagonist Hoe 140 and its influence on kallikrein. Gen Pharmacol 27:133-136
13. Sharma JN, Zeitlin IJ, Deodhar SD et al (1983) Detection of kallikrein-like activity in the inflamed synovial tissue. Arch Int Pharmacodyn Ther 262:279-286
14. Sharma JN, Zubaid M, Khan BZSJ et al (2000) Pathophysiological activities of the kallikrein-kinin system with emphasis on the cardiovascular disorders. Inflammopharmacology 8:219-241
15. Star MS, West GB (1967) Bradykinin and oedema formation in heated paw of rats. Br J Pharmacol 31:178-184
16. Van Arman CG, Nuss GW (1969) Plasma bradykininogen levels in adjuvant arthritis and carrageenan inflammation. J Pathol 99:245-250
17. Waller DG, Bhatia SS, Campbell SK et al (1990) active and inactive urinary kallikrein in man: effect of dieresis and antidiuresis. Clin Sci 79:117-121
18. Yamaguchi Y, Tanaka Y, Yamada K et al (1989) Abnormal lipid metabolism in adjuvant arthritic rats. Jpn J Pharmacol 50:377-386
19. Zach HP, Werle E (1972) Changes in kininogen content of serum and some organs during injury and inflammation in rats. Adv Exp Med Biol 21:371-379
20. Zach HP, Werle E (1973) Uber den kininnogen-gehalt von serum und plasma nach gewebsschadigung bei ratten. Arch Pharmacol 276:167-173